Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition

A multitude of disease and therapy related factors drive the frequent development of kidney disorders in cancer patients. Along with chemotherapy, the newer targeted therapeutics can also cause kidney dysfunction through on and off-target mechanisms. Interestingly, among the small molecule inhibitor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Kidney international 2021-12, Vol.100 (6), p.1214-1226
Hauptverfasser:	Bai, Yuntao, Kim, Ji Young, Bisunke, Bijay, Jayne, Laura A., Silvaroli, Josie A., Balzer, Michael S., Gandhi, Megha, Huang, Kevin M., Sander, Veronika, Prosek, Jason, Cianciolo, Rachel E., Baker, Sharyn D., Sparreboom, Alex, Jhaveri, Kenar D., Susztak, Katalin, Bajwa, Amandeep, Pabla, Navjot Singh
Format:	Artikel
Sprache:	eng
Schlagworte:	acute kidney injury Animals BRAF kinase Cell Line, Tumor Drug Resistance, Neoplasm Ferrochelatase Humans Indoles - toxicity Kidney - metabolism Mice Mutation onconephrology protein kinase inhibitors Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism renal tubular epithelial cells Sulfonamides - toxicity Vemurafenib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!